Novo Nordisk's diabetes pill has better start than Ozempic, Trulicity and Victoza
Rybelsus, the diabetes pill developed by Novo Nordisk, has sold more in its second quarter on the market than the other GLP-1 analogues Ozempic, Trulicity and Victoza did during their second quarters.
BY KEVIN GRØNNEMANN, TRANSLATED BY CATHERINE BRETT
Although the coronavirus pandemic has now temporarily put the brakes on Novo Nordisk's work to launch its diabetes pill Rybelsus, which was approved in September last year, the drug has had a good start on the market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
